<DOC>
	<DOCNO>NCT00876161</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , systemic exposure experimental influenza ( flu ) treatment medication call DAS181 . DAS181 dry powder administer via oral inhalation use special device . Study participant include healthy non-smoking male female , age 18-65 . They give either DAS181 placebo . Participants remain clinic overnight watch health change 24 hour receive medication . Study procedures include : physical exam , chest x-ray , ECGs , lung function test , collection blood urine sample , throat swab . Follow-up visit occur study day 2 , 7 , 14 30 .</brief_summary>
	<brief_title>DAS181 Single Dose Escalation Study Healthy Adults</brief_title>
	<detailed_description />
	<criteria>Male female subject generally good health opinion investigator determine vital sign , medical history , target physical exam base medical history . Subjects must able verbalize understanding consent form , provide write informed consent verbalize willingness complete study procedure Be 18 65 year age ( inclusive ) , past 12 month . Subjects must weigh least 50 kg must Body Mass Index ( BMI ) great 35 . No recent history smoke past two year regardless clinical relevance . No history alcoholism alcohol abuse regardless clinical relevance . Electrocardiogram ( ECG ) clinically significant abnormality record screen visit : PR interval within 120 200 m , QRS interval &lt; 120 m , QTc interval ≤ 440 m . Blood pressure within normal limit ( systolic 90140mmHg ; diastolic 5090 mmHg ) heart rate 45 100 beat per minute . Chest Xray FEV1 result show clinically significant abnormality . Negative HIV , HBV , HCV screen test . Hemoglobin within provide range ( see Appendix 2 ) . White blood cell count platelet count within provide range ( see Appendix 2 ) . Alkaline phosphatase ( ALKP ) , total bilirubin , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , creatinine phosphokinase ( CPK ) , within provide range ( see Appendix 2 ) . Serum glucose within provide range ( see Appendix 2 ) . If nonfasting glucose abnormal , fast glucose measurement may measure place . If within provided range , subject may enrol . Serum creatinine within provide range ( see Appendix 2 ) . Activated partial thromboplastin time ( APTT ) , Fibrinogen within provide range ( see Appendix 2 ) . Urine glucose , protein , hemoglobin test dipstick urinalysis negative great trace . Menstruating female fail inclusion due positive urine dipstick hemoglobin may retested follow cessation menses . Female subject must postmenopausal ( one year great without menses ) , surgically incapable childbearing , practice acceptable method birth control . Acceptable method may include intrauterine device , spermicide barrier , abstinence hormonal contraception . A female subject must agree practice acceptable method birth control study period 12 week study terminates . She must negative serum pregnancy test screen visit negative urine pregnancy test day treatment prior study drug dosing . If male , agree use medically accept form contraception time enrollment 12 week study termination Subjects must test negative drug alcohol Have receive investigational drug vaccine within 8 week prior study drug dose serious adverse reaction hypersensitivity drug Have receive blood product within 6 month study enrollment Have liquid protein diet last month . Are allergic intolerant lactose . Have sickle cell disease Have use prescription drug , exclude hormonal contraception , within 7 day prior admission ( investigator 's discretion ) nonprescription drug ( include herbal supplement ) within 7 day prior admission ( investigator 's discretion ) . Existence surgical , medical , laboratory condition , judgment clinical investigator , might interfere safety , distribution , metabolism excretion drug Subjects concurrent respiratory disease ( e.g. , asthma , allergic rhinitis , chronic obstructive pulmonary disease , cystic fibrosis , emphysema , anaphylaxis ) . Subjects experience previous episode acute upper respiratory tract infection , pneumonia , otitis , bronchitis , sinusitis within 2 week prior screen . Subjects concurrent sustain respiratory symptom ( run nose , sore throat , sneeze , cough , wheeze ) . Subjects oral temperature 37.8°C ( 100°F ) . Subjects previous current history follow condition : renal , hepatic , cardiac , pulmonary , hematologic , muscular , neurological , metabolic , immunological disorder , hepatitis cirrhosis , transplant recipient , HIVinfection , immunosuppressive illness . Subjects cancer history hematologic malignancy . Cancer define active neoplastic disease exclude noninvasive basal cell carcinoma . Subjects surgery within 30 day initiation study . Female subject pregnant breastfeeding . Subjects donate lose 500 mL blood three month prior screen . Subjects clinically significant medical psychological condition would compromise subject 's safety , influence result study , affect subject 's ability participate study , impair subject 's ability provide inform consent . Subjects history drug dependence , psychiatric illness within 2 year study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Healthy Adults</keyword>
</DOC>